BioSpace News Archive

Advaxis announces that data from an earlier Phase 2 clinical study of axalimogene filolisbac (ADXS11-001) as a treatment for persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC) was accepted for publication in the May edition of peer-reviewed International Journal of Gynecological Cancer.

ThermoDox is Celsion’s proprietary, heat-activated liposomal encapsulation of doxorubicin for the treatment of primary liver cancer.

In conjunction with already identified patients in France, the company expects to complete enrollment in first half of 2018.

In addition, the Company announced that based on the FDA’s responses, it plans to apply for dual indications, both opioid use disorder and alcohol use disorder, within the same application.

Infantile Batten disease is an inherited fatal genetic disease that primarily affects the nervous system in newborns and progresses rapidly.

The study was published in the international journal Nature Communications.

In addition to bavituximab, the deal includes Avid’s other PS-targeting antibodies.

Opiant intends to pursue a 505(b)(2) development path, and anticipates the potential to submit a NDA for the drug and intranasal delivery device combination in 2020.

CEL-SCI announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 9:45 a.m.

The paper will be printed in the June issue of Current Opinion in Biotechnology.